This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The 2025 AHA Statistical Update is the product of a full years worth of effort in 2024 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members.
Stroke, Volume 56, Issue Suppl_1 , Page AWP56-AWP56, February 1, 2025. Introduction:Prior studies have shown the association between oral infection, white matter hyperintensity (WMH), a marker of cerebral small vessel disease (CSVD), and asymptomatic intracranial atherosclerosis (ICAS). CSVD was assessed using the log of WMH volume.
tim.hodson Mon, 03/31/2025 - 10:26 March 31, 2025 AGEPHA Pharma USA, LLC, has released clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease.
tim.hodson Mon, 02/03/2025 - 12:30 January 29, 2025 Roche announced today that the Tina-quant Lipoprotein (a) Gen.2 Tsimikas S and Marcovina S, Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week , J Am Coll Cardiol. measuring lipoprotein (a), or Lp(a), in nanomoles per liter (nmol/L).
Stroke, Volume 56, Issue Suppl_1 , Page AWP203-AWP203, February 1, 2025. Evidence has shown that carotid artery geometries are independently associated with ipsilateral MCA atherosclerosis. Demographic data, riskfactors and the history of ischemic stroke of all patients were recorded. 21.35), p<0.001).Conclusions:Both
Stroke, Volume 56, Issue Suppl_1 , Page ATP222-ATP222, February 1, 2025. We determined associations of baseline demographics, vascular riskfactors, clinical, laboratory variables, imaging variables, and in-hospital treatments with study outcome. The study outcome was recurrent ischemic stroke by day 30.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP8-ATMP8, February 1, 2025. Introduction:The role of alcohol consumption as an independent riskfactor for atherosclerosis remains controversial. Carotid intima-media thickness (CIMT) is a recognized marker of atherosclerosis and can serve as a predictor of cardiovascular events.
Stroke, Volume 56, Issue Suppl_1 , Page ATP293-ATP293, February 1, 2025. Background and Objectives:Left subclavian artery (LSA) is more prone to atherosclerosis than the right one. The study was designed to investigate whether aortic arch types (AAT) was associated with the lateralization of subclavian artery stenosis (SAS).Methods:In
tim.hodson Mon, 03/31/2025 - 10:26 March 31, 2025 AGEPHA Pharma USA, LLC, has highlighted clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease.
Stroke, Volume 56, Issue Suppl_1 , Page ATP326-ATP326, February 1, 2025. Non-cardioembolic stroke was defined as stroke from large artery atherosclerosis, small vessel disease, or other known mechanism. We compared baseline characteristics and riskfactors between patients with vs. without AF detected.
Stroke, Volume 56, Issue Suppl_1 , Page AWP276-AWP276, February 1, 2025. Patients (age 18 years) with clinical manifestations of arterial disease or riskfactors for atherosclerosis were included and classified into the VAH and non-VAH group. VAH and stenosis degree of the artery (i.e.,
Stroke, Volume 56, Issue Suppl_1 , Page ATP318-ATP318, February 1, 2025. Introduction:Elevated Low-Density-Lipoprotein Cholesterol (LDL-C) blood levels are a riskfactor for atherosclerosis. Lipid-lowering therapies mitigate the risk of atherothrombotic events.
Stroke, Volume 56, Issue Suppl_1 , Page ATP258-ATP258, February 1, 2025. Introduction:Mechanical thrombectomy (MT) devices were fundamentally designed for the treatment of cardioembolic (CE) strokes despite that 10-20% of large vessel occlusions (LVO) are caused by large artery atherosclerosis (LAA), which may not respond comparably.
Stroke, Volume 56, Issue Suppl_1 , Page ATP220-ATP220, February 1, 2025. Patients with clinically defined intracranial atherosclerotic vascular diseases or riskfactors of atherosclerosis were available. Patients with ICAS having no or only mild stenosis (30%) of the ipsilateral extracranial ICA (C1) were included.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP98-ATMP98, February 1, 2025. In addition, coronary heart disease (adjusted HR=1.674, 95% CI: 1.013-2.766, P=0.044) was identified as a riskfactor associated with composite outcome during the 1-year follow-up.
Stroke, Volume 56, Issue Suppl_1 , Page AWP293-AWP293, February 1, 2025. Introduction:Migraine sufferers are at an increased risk of ischemic stroke which is one of the leading causes of disability worldwide. Conclusion:We report a possible association between migraine sufferers on SSRIs and risk for incident stroke.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP18-AWMP18, February 1, 2025. This study investigates the association between CMB patterns and dementia risk in the community-based longitudinal AtherosclerosisRisk in Communities Neurocognitive Study (ARIC-NCS).Methods:All
Stroke, Volume 56, Issue Suppl_1 , Page AWP310-AWP310, February 1, 2025. Background:Vascular riskfactors, particularly in midlife, are associated with an increased risk of dementia, and smoking has been inversely associated with Parkinson's disease (PD) risk, but the role of these factors in PD-dementia (PDD) is less clear.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP107-ATMP107, February 1, 2025. Objective:Late-life vascular health and cerebrovascular disease have been identified as potential riskfactors for late-life depression (LLD). To assess cumulative vascular risk burden, the number of VRFs were counted and categorized as 0, 1, 2, or 3.
Stroke, Volume 56, Issue Suppl_1 , Page AWP388-AWP388, February 1, 2025. Introduction:Eicosanoids (EIC) are lipid mediators that play a systemic role in inflammation and, more specifically, in the brain, contribute to the process of neurovascular coupling. Results:Among the 9,444 participants included, the mean age was 57 (5.7 SD), and 43.2%
Stroke, Volume 56, Issue Suppl_1 , Page A135-A135, February 1, 2025. We aimed to evaluate the association between carotid artery tortuosity and the incidence of ischemic stroke.Methods:We analyzed 3D contrast-enhanced MRA datasets from 2,066 participants enrolled in the AtherosclerosisRisk in Communities (ARIC) Carotid MRI study.
Stroke, Volume 56, Issue Suppl_1 , Page AWP336-AWP336, February 1, 2025. Background:Trimethylamine N-oxide (TMAO), a gut microbiome-derived metabolite trimethylamine-containing nutrients, is mechanistically linked to atherosclerosis progression and platelet aggregation, leading to cardiovascular disease. p< 0.05).
Nature Reviews Cardiology, Published online: 02 January 2025; doi:10.1038/s41569-024-01108-9 In this Review, Yvan-Charvet and colleagues discuss how cardiovascular riskfactors and metabolic modifiers of atherosclerosis influence metabolism-dependent haematopoietic stem cell skewing (haematometabolism) and efferocyte reprogramming (efferotabolism) (..)
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content